UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | E | F | G | H | J | K | L | M | N | P | R | S | T | U | V | W | Z
Number of items: 94.

A

Alley, MC; Hollingshead, MG; Pacula-Cox, CM; Waud, WR; Hartley, JA; Howard, PW; Gregson, SJ; ... Sausville, EA; + view all (2002) Efficacy evaluations of SJG-136 (NSC 694501), a novel pyrrolobenzodiazepine dimer with broad spectrum antitumor activity. In: (pp. 315-).

Ameer-Beg, SM; Barber, PR; Hodgkiss, RJ; Locke, RJ; Newman, RG; Tozer, GM; Vojnovic, B; (2002) Application of multiphoton steady state and lifetime imaging to mapping of tumour vascular architecture in vivo. In: (pp. pp. 85-95).

Ardeshna, K; Smith, P; Norton, A; Hancock, B; Hoskin, PJ; (2002) The long term impact of a watch and wait policy vs immediate systemic treatment for asymptomatic advanced stage indolent non Hodgkin's lymphoma: results of a British National Lymphoma randomized trial. In: (pp. 76-).

Arkenau, HT; Widjaja, A; (2002) An unusual case of cholestasis and makrohematuria in a 52-year-old patient. Medizinische Klinik , 97 (8) pp. 480-483. 10.1007/s00063-002-1183-3.

Atalay, G; Biganzoli, L; Renard, F; Paridaens, R; Batter, V; Coleman, R; Piccart, M; ... Cofer, T; + view all (2002) Clinical outcome of breast cancer patients with liver metastases in the anthracycline-taxane era. Breast Cancer Research and Treatment , 76 138-.

B

Batey, MA; Wright, JG; Azzabi, A; Newell, DR; Lind, MJ; Calvert, AH; Boddy, AV; (2002) Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). EUR J CANCER , 38 (8) 1081 - 1089.

Bentzen, SM; Saunders, MI; Dische, S; (2002) From CHART to CHARTWEL in non-small cell lung cancer: Clinical radiobiological modelling of the expected change in outcome. Clinical Oncology , 14 (5) pp. 372-381.

Boddy, AV; Todd, R; Verrill, M; Sludden, J; Fishwick, K; Robson, L; Cassidy, J; ... Calvert, AH; + view all (2002) Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study. European Journal of Cancer , 38 98-.

Bomanji, JB; Syed, R; Brock, C; Jankowska, P; Dogan, A; Costa, DC; Ell, PJ; (2002) Case 2. Pitfalls of positron emission tomography for assessing residual mediastinal mass after chemotherapy for Hodgkin's disease. Journal of Clinical Oncology , 20 (15) pp. 3347-3349.

Bowen, RL; Francis, RJ; Green, AJ; Baig, S; Knell, V; Buscombe, JR; Hilson, AJW; (2002) How accurately can the oncologist report FDG-PET tumour response using the ADAC vertex plus dual-headed gamma camera? BRIT J CANCER , 86 S102 - S102.

Braybrooke, JP; Slade, A; Gibson, R; Deplanque, G; Madhusudan, S; Makris, A; (2002) Phase one study of MetXia-P450 gene therapy for patients with advanced breast cancer or melanoma. In: (pp. 22a-).

Brett, BT; Smith, SC; Bouvier, CV; Michaeli, D; Hochhauser, D; Davidson, BR; Kurzawinski, TR; ... Caplin, ME; + view all (2002) Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. Journal of Clinical Oncology , 20 (20) pp. 4225-4231. 10.1200/JCO.2002.11.151.

Bunn, PA; Calvert, H; (2002) Pemetrexed, a novel multitargeted antifolate: Current development and future directions - Introduction. SEMIN ONCOL , 29 (2) 1 - 2. 10.1053/sonc.2002.30757.

Burcombe, RJ; Makris, A; Pittam, M; Lowe, J; Emmott, J; Wong, WL; (2002) Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [F-18]- fluorodeoxyglucose positron emission tomography. European Journal of Cancer , 38 (3) pp. 375-379.

Burcombe, RJ; Makris, A; Wilson, GD; (2002) Evaluation of topoisomerase II-alpha as a predictor of clinical and pathological response to neoadjuvant chemotherapy in operable breast cancer. In: (pp. 447a-).

Burger, AM; Fiebig, HH; Hagan, DR; Tiberghien, A; Howard, PW; Schultz, R; Hartley, JA; (2002) The monomer pyrrolobenzodiazepine (PBD) DNA minor-groove binding agent DRH-417 (NSC 709119) shows pre-clinical activity in human renal cell carcinoma. In: (pp. 5719-).

C

Calvert, H; Bunn, PA; (2002) Future directions in the development of pemetrexed. SEMINARS IN ONCOLOGY , 29 (2) 54 - 61. 10.1053/sonc.2002.30761.

Chow, E; Coia, L; Wu, J; Nanjan, N; Kirkbride, P; Hoskin, PJ; (2002) Debate: this house believes that multiple-fraction radiotherapy is a barrier to referral for palliative radiotherapy for bone metastases. Current Oncology , 9 pp. 60-66.

Chow, E; Wu, JSY; Hoskin, P; Coia, LR; Bentzen, SM; Blitzer, PH; (2002) International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiotherapy And Oncology , 64 (3) pp. 275-280.

Chow, E; Wu, JSY; Hoskin, P; Coia, LR; Bentzen, SM; Blitzer, PH; (2002) International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. International Journal of Cancer p. 7.

Cooke, SP; Pedley, RB; Boden, R; Begent, RHJ; Chester, KA; (2002) In vivo tumor delivery of a recombinant single chain Fv::tumor necrosis factor-alpha fusion [correction of factor: a fusion] protein. Bioconjug Chem , 13 (1) pp. 7-15.

Cooke, SP; Pedley, RB; Boden, R; Begent, RHJ; Chester, KA; (2002) In vivo tumor delivery of a recombinant single chain fv :: tumor necrosis factor-alpha fusion protein (vol 13, pg 7, 2002). BIOCONJUGATE CHEM , 13 (2) 385 - 385. 10.1021/bc020015h.

Cooke, SP; Pedley, RB; Boden, R; Begent, RHJ; Chester, KA; (2002) In vivo tumor delivery of a recombinant single-chain Fv::Tumor necrosis factor: A fusion protein. Bioconjugate Chemistry , 13 (1) pp. 7-15. 10.1021/bc000178a.

Cooke, SP; Pedley, RB; Boden, R; Begent, RHJ; Chester, KA; (2002) In vivo tumor delivery of a recombinant single-chain Fv::Tumor necrosis factor: A fusion protein. BIOCONJUGATE CHEM , 13 (1) 7 - 15. 10.1021/bc000178a.

Craddock, C; Hochhauser, D; (2002) Realising the potential of targeted therapies in oncology. LANCET , 360 (9331) 424 - 425.

E

El-Emir, E; Petrie, ; I, A; Boxer, ; G, M; Boden, ; R, ; ... R, HJAPRB; + view all (2002) Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. In: (Proceedings) Proceedings BACR, Br J Cancer. (pp. 257-).

El-Emir, E; Petrie, IA; Boxer, GM; Boden, R; Dearling, JLJ; Raleigh, JA; Mantavani, A; ... Pedley, RB; + view all (2002) Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. BRIT J CANCER , 86 S112 - S112.

F

Flynn, AA; Green, AJ; Pedley, RB; Boxer, GM; Dearling, J; Watson, R; Boden, R; (2002) A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection. Cancer , 94 (4 Suppl) pp. 1249-1257.

Ford, HER; Mitchell, F; Cunningham, D; Farrugia, DC; Hill, ME; Rees, C; Calvert, AH; ... Jackman, AL; + view all (2002) Patterns of elevation of plasma 2 '-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. CLIN CANCER RES , 8 (1) 103 - 109.

Fordham-Skelton, AP; Chilley, P; Lumbreras, V; Reignoux, S; Fenton, TR; Dahm, CC; Pages, M; (2002) A novel higher plant protein tyrosine phosphatase interacts with SNF1-related protein kinases via a KIS (kinase interaction sequence) domain. Plant J , 29 (6) pp. 705-715.

Forster, MD; Braybrooke, J; Madhusudan, S; Kaur, K; Hoare, S; Balkwill, F; Ganesan, TS; ... Harris, AL; + view all (2002) A phase II trial using etanercept, a recombinant tumour necrosis factor antagonist, in metastatic breast cancer. In: (pp. S38-S38). NATURE PUBLISHING GROUP

Francis, RJ; Green, AJ; Baig, S; Knell, V; Frisken, I; Bowen, RL; Hilson, AJW; ... Begent, RHJ; + view all (2002) A novel approach to assessing response to chemotherapy using hybrid camera FDG PET. BRIT J CANCER , 86 S100 - S100.

Francis, RJ; Sharma, SK; Springer, C; Green, AJ; Hope-Stone, LD; Sena, L; Martin, J; ... Begent, RHJ; + view all (2002) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. British Journal of Cancer , 87 (6) pp. 600-607. 10.1038/sj.bjc.6600517.

G

Gasco, M; Sullivan, A; Repellin, C; Brooks, L; Farrell, PJ; Tidy, JA; Dunne, B; ... Crook, T; + view all (2002) Coincident inactivation of 14-3-3σ and p16INK4a is an early event in vulval squamous neoplasia. Oncogene , 21 (12) pp. 1876-1881. 10.1038/sj.onc.1205256.

Gore, M; Oza, A; Rustin, G; Malfetano, J; Calvert, H; Clarke-Pearson, D; Carmichael, J; ... Fields, SZ; + view all (2002) A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. EUR J CANCER , 38 (1) 57 - 63.

Gupta, N; Saleem, A; Osman, S; Hoskin, P; Price, PM; Aboagye, EO; (2002) Carbogen and nicotinamide selectively increase chemotherapy delivery and blood flow to liver metastasis. British Journal of Cancer , 86 S14-S14.

H

Harney, J; Goodchild, K; Glynne-Jones, R; Phillips, H; Hoskin, PJ; Saunders, MI; (2002) A Phase I/II Study of CHARTWEL with concurrent chemotherapy in locally advanced inoperable carcinoma of the oesphagus. In: (pp. S27-).

Harney, J; Goodchild, K; Glynne-Jones, R; Phillips, H; Hoskin, PJ; Saunders, MI; (2002) A phase II study of CHARTWEL with concurrent chemotherapy in locally advanced, inoperable carcinoma of the oesophagus. In: (pp. 83-).

Harney, J; Shah, N; Joiner, M; Short, S; Saunders, MI; (2002) Low dose hyper-sensitivity- does it occur in normal skin? In:

Harney, J; Shah, N; Short, SC; Joiner, M; Saunders, MI; (2002) Low dose hyper-radiosensitivity - does it exist in normal skin? In: (pp. S57-).

Harney, J; Short, SC; Saunders, MI; (2002) Low dose hyper-radiosensitivity - A clinical assessment. In: (pp. S56-).

Hartley, JA; Spanswick, VJ; Pedley, RB; Hollingshead, MG; Alley, MC; Schultz, R; Gregson, SJ; ... Thurston, DE; + view all (2002) In vitro antitumor activity and in vivo DNA interstrand crosslinking by the novel pyrrolobenzodiazepine dimer SJG-136 (NSC 694501). In: (pp. 2432-).

Hartley, JA; Spanswick, VJ; Pedley, RB; Hollingshead, MG; Alley, MC; Schultz, R; Gregson, SJ; ... D, E; + view all (2002) In vitro activity and in vivo DNA interstrand crosslinking by the novel pyrrolobenzodiazepine dimer SJG-136 (NSC 694501). In: (Proceedings) Proceedings American Association for Cancer Research. (pp. 489-).

Hoskin, P; (2002) Secondary malignancies after radiotherapy. The Lancet Oncology , 3 (9) pp. 577-578.

Hoskin, PJ; (2002) Conformal radiotherapy to the prostate: are bigger fields better? Clinical Oncology , 14 (4) pp. 296-297.

Hoskin, PJ; (2002) FDG PET in the management of lymphoma: a clinical perspective. European Journal of Nuclear Medicine and Molecular Imaging , 29 (4) pp. 449-451.

Hoskin, PJ; (2002) Tumour hypoxia and vascularity in lymphoma. In: (pp. 615-).

Hoskin, PJ; (2002) Radiotherapy in cancer pain management. In: Rice, ASC and Warfield, CA and Justins, D and Eccleston, C and Arnold, E, (eds.) Clinical Pain Management. (pp. 253-258). : London.

Hoskin, PJ; (2002) Radiotherapy in palliative care. In: Rice, ASC and Warfield, CA and Justins, D and Eccleston, C and Arnold, E, (eds.) Clinical Pain Management. (pp. 281-292). Arnold: London.

Hoskin, PJ; Bownes, P; Summers, A; (2002) The influence of applicator angle on dosimetry in vaginal vault brachytherapy. British Journal of Radiology , 75 (891) pp. 234-237.

Hoskin, PJ; Grover, A; Bhana, R; (2002) Optimal radiotherapy dose for metastatic spinal canal compression. British Journal of Cancer , 86 S20-S20.

Hoskin, PJ; Morgan, DAL; Robinson, M; (2002) Erythropoetin supplementation for radical radiotherapy in head and neck cancer: an interim analysis of a randomized phase III trial. In: (pp. 83-).

Howard, TT; Lingerfelt, BM; Purnell, BL; Scott, AE; Price, CA; Townes, HM; McNulty, L; ... Lee, M; + view all (2002) Novel furano analogues of duocarmycin C1 and C2: Design, synthesis, and biological evaluation of seco-iso- cyclopropylfurano[2,3-e]indoline (seco-iso-CFI) and seco- cyclopropyltetrahydrofurano[2,3-f]quinoline (seco-CFQ) analogues. Bioorganic and Medicinal Chemistry , 10 (9) pp. 2941-2952.

J

Jones, B; Aird, E; Colyer, H; Dobbs, J; Harris, R; Hoskin, P; McKenzie, A; (2002) United Kingdom Radiation Oncology 1 conference (UKRO 1): Accuracy and uncertainty in radiotherapy. BRITISH JOURNAL OF RADIOLOGY , 75 (892) pp. 297-306. 10.1259/bjr.75.892.750297.

K

Kirkby, N; Faraday, DBF; Short, S; C, W; M, J; M C, B; N, G; (2002) Mathematical modelling to develop a novel radiotherapy schedule for high grade brain tumours, based on phase distribution of low-dose hypersensitivity in human glioma cell lines. In:

L

Lee, SM; James, LE; Mohamed-Ali, V; Boschoff, C; Snee, M; Brock, C; Leary, A; ... Prendiville, J; + view all (2002) A phase II study of carboplatin/etoposide with thalidomide in small cell lung cancer (SCLC). In: (Proceedings) Oral presentation. 2002 ASCO Annual Meeting/38th Annual Meeting, Orlando, FL.. (pp. 1251-). Proceedings of the American Society of Clinical Oncology

Lee, YC; Boehm, MK; Chester, KA; Begent, RHJ; Perkins, SJ; (2002) Reversible dimer formation and stability of the anti-tumour single-chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FT-IR spectroscopy. J MOL BIOL , 320 (1) 107 - 127. 10.1016/S0022-2836(02)00403-5.

Leonard, P; Seymour, MT; James, R; Hochhauser, D; Ledermann, JA; (2002) Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. BRIT J CANCER , 87 (11) 1216 - 1220. 10.1038/sj.bjc.6606641.

M

Makris, A; Burcombe, RJ; Wilson, GD; Richman, PI; Allen, S; Wright, D; Pittam, M; (2002) Comparison of clinical, radiological and pathological assessment of response to neoadjuvant chemotherapy for primary breast cancer. European Journal of Cancer , 38 268-.

Mayer, A; Spencer, DIR; Tolner, B; Purdy, D; Begent, RHJ; Chester, K; (2002) A recombinant fusion protein with potentially reduced immunogenicity for ADEPT. British Journal of Cancer , 86 S117-S117.

Mayer, A; Spencer, DIR; Tolner, B; Purdy, D; Begent, RHJ; Chester, K; (2002) A recombinant fusion protein with potentially reduced immunogenicity for ADEPT. BRIT J CANCER , 86 S117 - S117.

McHugh, PJ; Kiakos, K; Hartley, JA; Lee, M; (2002) The Rad6 pathway is involved in the nucleotide excision repair of DNA minor groove adducts. In: (pp. 5103-).

N

Nicholson, PW; Harland, SJ; (2002) Survival prospects after screen-detection of prostate cancer. BJU INT , 90 (7) 686 - 693. 10.1046/j.1464-4096.2002.03005.x.

P

Patel, K; Stein, R; Benvenuti, S; Zvelebil, MJ; (2002) Combinatorial use of mRNA and two-dimensional electrophoresis expression data to choose relevant features for mass spectrometric identification. PROTEOMICS , 2 (10) pp. 1464-1473. 10.1002/1615-9861(200210)2:10<1464::AID-PROT1464>3.0.CO;2-9.

Pedley, RB; El-Emir, E; Flynn, AA; Boxer, GM; Dearling, J; Raleigh, JA; Hill, SA; ... Begent, RHJ; + view all (2002) Synergy between vascular targeting agents and antibody-directed therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS , 54 (5) 1524 - 1531.

Petrie, IA; Flynn, AA; Pedley, RB; Green, AJ; El-Emir, E; Dearling, JLJ; Boxer, GM; ... Begent, RHJ; + view all (2002) Spatial accuracy of 3D reconstructed radioluminographs of serial tissue sections and resultant absorbed dose estimates. PHYS MED BIOL , 47 (20) 3651 - 3661.

Pinto, M; (2002) Induction and rejoining of DNA double-strand breaks in human cells after exposure to ionising radiation: an experimental and modelling approach. Doctoral thesis , University of London. Green open access
file

Plummer, R; Ghielmini, M; Calvert, P; Voi, M; Renard, J; Gallant, G; Gupta, E; ... Sessa, C; + view all (2002) Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. CLIN CANCER RES , 8 (9) 2788 - 2797.

R

Rudd, RM; Gower, NH; James, LE; Gregory, W; Eisen, T; Lee, SM; et, A; (2002) A phase III randomised comparison of gemcitabine/carboplatin with mitomycin/ifosfamide/cisplatin in advanced non-small cell lung cancer. In: (Proceedings) Oral presentation. 2002 Annual ASCO Meeting/38th Annual Meeting, Orlando, FL.. (pp. 1164-). Proceedings of the American Society of Clinical Oncology

S

Saunders, MI; (2002) Chart and chemotherapy. Clinical Oncology , 14 (4) pp. 331-332.

Schellens, JHM; Heinrich, B; Lehnert, M; Gore, ME; Kaye, SB; Dombernowsky, P; Paridaens, R; ... Hanauske, AR; + view all (2002) Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies. INVEST NEW DRUG , 20 (1) 83 - 93.

Sharma, SK; Pedley, RB; Bhatia, J; Irwin, HL; El-Emir, E; Boxer, GM; Boden, RW; ... R, HJ; + view all (2002) Antibody-directed enzyme prodrug therapy (ADEPT): comparison in two colorectal carcinoma xenografts. In: (Proceedings) proceedings AmericanAssociation for Cancer Research. (pp. 943-).

Short, SC; Harney, J; Dopson, F; Saunders, MI; (2002) The effects of low-dose fractionated radiation on sarcomas- experimental and clinical data. British Journal of Cancer , 86 S56-S57.

Sibtain, A; Hill, S; Goodchild, K; Shah, N; Saunders, M; Hoskin, PJ; (2002) The modification of human tumour blood flow using pentoxifylline, nicotinamide and carbogen. Radiotherapy And Oncology , 62 (1) pp. 69-76.

Sibtain, A; Wilson, GD; Hoskin, PJ; (2002) Hypoxia in bladder cancer: Validation of intrinsic markers with pimonidazole and their influence on clinical outcome after accelerated radiotherapy with carbogen and nicotinamide. British Journal of Cancer , 86 S28-S29.

Spalding, DRC; Hochhauser, D; Hartley, J; Davidson, B; (2002) Heterogeneity of response to chemotherapy in liver tumours evaluated by the comet assay in an isolated perfused human liver. British Journal Of Surgery , 89 p. 50.

Spanswick, VJ; Craddock, C; Sekhar, M; Mahendra, P; Shankaranarayana, P; Hughes, RG; Hochhauser, D; (2002) Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. BLOOD , 100 (1) 224 - 229. Green open access
file

Spencer, DIR; Robson, L; Purdy, D; Whitelegg, NR; Michael, NP; Bhatia, J; Sharma, SK; ... Chester, KA; + view all (2002) A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics. PROTEOMICS , 2 (3) 271 - 279.

Spender, LC; Cornish, GH; Sullivan, A; Farrell, PJ; (2002) Expression of transcription factor AML-2 (RUNX3, CBF(alpha)-3) is induced by Epstein-Barr virus EBNA-2 and correlates with the B-cell activation phenotype. J Virol , 76 (10) pp. 4919-4927.

Sullivan, A; Yuille, M; Repellin, C; Reddy, A; Reelfs, O; Bell, A; Dunne, B; ... Crook, T; + view all (2002) Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene , 21 (9) pp. 1316-1324. 10.1038/sj.onc.1205207.

Szekely, Z; Kosakowska-Cholody, T; Hartley, JA; Michejda, CJ; (2002) Coupling minor groove binders with intercalators, an attempt to design chemical gene knockout agents. In: (pp. 2428-).

T

Thomas, HD; Porter, DJ; Bartelink, I; Nobbs, JR; Cole, M; Elliott, S; Newell, DR; ... Boddy, AV; + view all (2002) Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide. BRIT J CLIN PHARMACO , 53 (1) 83 - 91.

Thomas, R; Makris, A; Bloomfield, D; Godward, S; Moody, M; (2002) Empowering patients to make informed treatment decisions based on tolerability, quality of life patient preference. A comparison of letrozole and anastrazole in a multicentre, randomised, single-blind cross over study. European Journal of Cancer , 38 171-.

Toth, JL; Price, CA; Madsen, EC; Handl, HL; Hudson, SJ; Hubbard, RB; Bowen, JP; ... Lee, M; + view all (2002) Sequence selective recognition of DNA by hairpin conjugates of a racemic seco-cyclopropaneindoline-2-benzofurancarboxamide and polyamides. BIOORG MED CHEM LETT , 12 (16) 2245 - 2248.

Toth, JL; Price, CA; Madsen, EC; Handl, HL; Hudson, SJ; Hubbard, RB; Bowen, JP; ... Lee, M; + view all (2002) Sequence selective recognition of DNA by hairpin conjugates of a racemic seco-cyclopropaneindoline-2-benzofurancarboxamide and polyamides. Bioorg Med Chem Lett , 12 (16) pp. 2245-2248.

Trent, S; Kong, A; Short, SC; Traish, D; Ashley, S; Dowe, A; Hines, F; (2002) Temozolomide as second-line chemotherapy for relapsed gliomas. Journal of Neuro-Oncology , 57 (3) pp. 247-251.

U

UCL, AR; (2002) Achievements: UCL's academics conducted pioneering work at the forefront of their disciplines during this year. pp. 12-13.

UCL, PS; (2002) Thalidomide to be used in cancer fight. 44-.

V

Vassileva, V; Millar, A; Briollais, L; Chapman, W; Bapat, B; (2002) Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. CANCER RESEARCH , 62 (14) pp. 4095-4099.

Venables, K; Winfield, E; Aird, E; Hoskin, PJ; (2002) Three-dimensional distribution of radiation within the breast: an intercomparison of departments participating in the START trial of breast radiotherapy fractionation. International Journal of Radiation Oncology Biology Physics , 55 pp. 271-279.

W

Winfield, E; Deighton, A; Venables, K; Hoskin, PJ; Aird, EGA; (2002) Survey of UK breast radiotherapy techniques: Background prior to the introduction of the quality assurance programme for the START (Standardisation of Radiotherapy) Trial in breast cancer. Clinical Oncology , 14 (4) pp. 267-271.

Wong, WL; Campbell, H; Saunders, M; (2002) Positron emission tomography (PET) - Evaluation of 'indeterminate pulmonary lesions'. Clinical Oncology , 14 (2) pp. 123-128.

Z

Zhang, J; Vanhaesebroeck, B; Rittenhouse, SE; (2002) Human platelets contain p110 delta phosphoinositide 3-kinase. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS , 296 (1) pp. 178-181. 10.1016/S0006-291X(02)00744-1.

Zhang, J; Vanhaesebroeck, B; Rittenhouse, SE; (2002) Human platelets contain p110 delta phosphoinositide 3-kinase. BIOCHEM BIOPH RES CO , 296 (1) 178 - 181.

This list was generated on Sun Jun 17 01:46:37 2018 BST.